These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38979188)

  • 1. A Prodrug Strategy to Reposition Atovaquone as a Long-Acting Injectable for Malaria Chemoprotection.
    Gupta AK; Eliasen AM; Andahazy W; Zhou F; Henson K; Chi V; Woods AK; Joseph SB; Kuhen KL; Wisler J; Ramachandruni H; Duffy J; Burrows JN; Vadas E; Slade A; Schultz PG; McNamara CW; Chatterjee AK
    bioRxiv; 2024 Jun; ():. PubMed ID: 38979188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-acting injectable atovaquone nanomedicines for malaria prophylaxis.
    Bakshi RP; Tatham LM; Savage AC; Tripathi AK; Mlambo G; Ippolito MM; Nenortas E; Rannard SP; Owen A; Shapiro TA
    Nat Commun; 2018 Jan; 9(1):315. PubMed ID: 29358624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ELQ-331 as a prototype for extremely durable chemoprotection against malaria.
    Smilkstein MJ; Pou S; Krollenbrock A; Bleyle LA; Dodean RA; Frueh L; Hinrichs DJ; Li Y; Martinson T; Munar MY; Winter RW; Bruzual I; Whiteside S; Nilsen A; Koop DR; Kelly JX; Kappe SHI; Wilder BK; Riscoe MK
    Malar J; 2019 Aug; 18(1):291. PubMed ID: 31455339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulation and characterization of atovaquone nanosuspension for improved oral delivery in the treatment of malaria.
    Borhade V; Pathak S; Sharma S; Patravale V
    Nanomedicine (Lond); 2014 Apr; 9(5):649-66. PubMed ID: 23927590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Injectable anti-malarials revisited: discovery and development of new agents to protect against malaria.
    Macintyre F; Ramachandruni H; Burrows JN; Holm R; Thomas A; Möhrle JJ; Duparc S; Hooft van Huijsduijnen R; Greenwood B; Gutteridge WE; Wells TNC; Kaszubska W
    Malar J; 2018 Nov; 17(1):402. PubMed ID: 30384848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerated reactive dissolution model of drug release from long-acting injectable formulations.
    Sonntag E; Kolář J; Djukaj S; Lehocký R; Štěpánek F
    Eur J Pharm Biopharm; 2023 Aug; 189():122-132. PubMed ID: 37321329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fully synthetic injectable depots with high drug content and tunable pharmacokinetics for long-acting drug delivery.
    Ho DK; LeGuyader C; Srinivasan S; Roy D; Vlaskin V; Chavas TEJ; Lopez CL; Snyder JM; Postma A; Chiefari J; Stayton PS
    J Control Release; 2021 Jan; 329():257-269. PubMed ID: 33217474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Acting Injectable Statins-Is It Time for a Paradigm Shift?
    Tatham LM; Liptrott NJ; Rannard SP; Owen A
    Molecules; 2019 Jul; 24(15):. PubMed ID: 31344834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of macrophage and angiogenesis inhibition on the drug release and absorption from an intramuscular sustained-release paliperidone palmitate suspension.
    Darville N; van Heerden M; Mariën D; De Meulder M; Rossenu S; Vermeulen A; Vynckier A; De Jonghe S; Sterkens P; Annaert P; Van den Mooter G
    J Control Release; 2016 May; 230():95-108. PubMed ID: 27067365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral Agent.
    Subramanian R; Tang J; Zheng J; Lu B; Wang K; Yant SR; Stepan GJ; Mulato A; Yu H; Schroeder S; Shaik N; Singh R; Wolckenhauer S; Chester A; Tse WC; Chiu A; Rhee M; Cihlar T; Rowe W; Smith BJ
    Mol Pharm; 2023 Dec; 20(12):6213-6225. PubMed ID: 37917742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-acting intramuscular injections of ELQ-331, an antimalarial agent.
    Karunakaran D; Mutyam SK; Fu M; Chen J; Pham KHN; Pou S; Winter RW; Nilsen A; Dodean RA; Smilkstein MJ; Riscoe MK; Shankar G
    Eur J Pharm Sci; 2024 Jul; 198():106795. PubMed ID: 38729224
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Liu R; Li G; Li M; Wang B; Zhang D; Xu L; Zhao L; Liao R; Xu Q; Bei Z-C; Song Y
    Microbiol Spectr; 2024 Jul; 12(7):e0063024. PubMed ID: 38780257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Three newly registered drugs in the Netherlands for the treatment and chemoprophylaxis of malaria: atovaquone-proguanil, artemether-lumefantrine and artemotil].
    Kager PA
    Ned Tijdschr Geneeskd; 2003 Feb; 147(7):291-5. PubMed ID: 12622006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atovaquone oral bioavailability enhancement using electrospraying technology.
    Darade A; Pathak S; Sharma S; Patravale V
    Eur J Pharm Sci; 2018 Jan; 111():195-204. PubMed ID: 28974387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyaluronidase impacts exposures of long-acting injectable paliperidone palmitate in rodent models.
    Pertinez H; Kaushik A; Curley P; Arshad U; El-Khateeb E; Li SY; Tasneen R; Sharp J; Kijak E; Herriott J; Neary M; Noë M; Flexner C; Nuermberger E; Owen A; Ammerman NC
    bioRxiv; 2024 Mar; ():. PubMed ID: 38496644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinically relevant atovaquone-resistant human malaria parasites fail to transmit by mosquito.
    Balta VA; Stiffler D; Sayeed A; Tripathi AK; Elahi R; Mlambo G; Bakshi RP; Dziedzic AG; Jedlicka AE; Nenortas E; Romero-Rodriguez K; Canonizado MA; Mann A; Owen A; Sullivan DJ; Prigge ST; Sinnis P; Shapiro TA
    Nat Commun; 2023 Oct; 14(1):6415. PubMed ID: 37828012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria.
    McKeage K; Scott L
    Drugs; 2003; 63(6):597-623. PubMed ID: 12656656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abbreviated atovaquone-proguanil prophylaxis regimens in travellers after leaving malaria-endemic areas: A systematic review.
    Savelkoel J; Binnendijk KH; Spijker R; van Vugt M; Tan K; Hänscheid T; Schlagenhauf P; Grobusch MP
    Travel Med Infect Dis; 2018; 21():3-20. PubMed ID: 29242073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atovaquone/proguanil for the prophylaxis and treatment of malaria.
    Patel SN; Kain KC
    Expert Rev Anti Infect Ther; 2005 Dec; 3(6):849-61. PubMed ID: 16307498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.